Objective: The aim of this study was to indirectly compare the efficacy and safety of anti-tumor necrosis factor α (TNFα) agents and an interleukin (IL)-17A inhibitor Secukinmuab for the treatment of ankylosing spondy-litis (AS). Methods: Literatures were searched in Pubmed, Medline, Embase and the Cochrane library to screen citations from January 1996 to December 2015. The mixed treatment comparison (MTC) meta-analysis within a Bayesian framework was performed by WinBUGS14 software. The

more »

... ion of patients reaching ASAS20 and ASAS40 improvement by the assessment of Spondyloarthritis International Society response criteria index at week 12 was used as efficacy end point. Results: There was no significant difference between the five anti-TNFα agents and Secukinmuab regarding their efficacy and safety. We found that infliximab may have a better effect in improving ASAS20 than the other drugs and ct-p13 may have a better effect in improving ASAS40 than the other drugs during 12 week therapy, although there were no statistical differences. Conclusion: Allsix agents have similar effects in improvement of ASAS20, ASAS40, and safety. However, infliximab and ct-p13 trended to be superior to the other four agents in terms of ASAS20 and ASAS40 during 12 week treatment. IL-17A can be a potential therapeutic target in spondyloarthritis.